News
Select year:
2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016
Click here for announcements regarding managers transactions.
Click here for news in Danish.
December 08, 2016 | Company Announcements
Bavarian Nordic Introduces New Incentive Programs for Executive Management and Employees November 23, 2016 | Company Announcements
Bavarian Nordic Completes Enrollment of Phase 3 Non-inferiority Study of IMVAMUNE® Smallpox VaccineNovember 23, 2016 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise November 09, 2016 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2016 October 18, 2016 | Company Announcements
Bavarian Nordic Announces Initiation of Phase 2 Clinical Trial of RSV Vaccine September 13, 2016 | Company Announcements
Bavarian Nordic Issues Financial Calendar for 2017August 31, 2016 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise August 17, 2016 | Company Announcements
Bavarian Nordic Announces First Half 2016 Results August 15, 2016 | Company Announcements
Bavarian Nordic Announces Drug Supply Agreement with Bristol-Myers Squibb for NSCLC Clinical Study July 27, 2016 | Company Announcements
Bavarian Nordic Announces Initiation of NIH Sponsored Phase 1 Trial of MVA-BN-based Yellow Fever VaccineJune 15, 2016 | Company Announcements
Bavarian Nordic Announces Expansion of IMVAMUNE Orders from Canadian Government May 27, 2016 | Company Announcements
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back ProgramMay 27, 2016 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise May 26, 2016 | Company Announcements
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme ObligationsMay 23, 2016 | Company Announcements
Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly PopulationsMay 19, 2016 | Company Announcements
Bavarian Nordic Announces USD 100 Million Supply Contract for IMVAMUNE Smallpox Vaccine with the U.S. Government May 13, 2016 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Three Months of 2016 April 30, 2016 | Company Announcements
Total number of voting rights and share capital in Bavarian Nordic A/S April 20, 2016 | Company Announcements
Bavarian Nordic A/S – Report on the Results of the Annual General Meeting, held 20 April 2016April 18, 2016 | Company Announcements
Bavarian Nordic A/S Completes Registration of Share Capital IncreaseApril 18, 2016 | Company Announcements
Bavarian Nordic A/S Completes a Private Placement at Market PriceApril 14, 2016 | Company Announcements
Bavarian Nordic A/S Announces Pricing of its Private PlacementApril 13, 2016 | Company Announcements
Bavarian Nordic A/S Announces Launch of Private PlacementMarch 31, 2016 | Company Announcements
Total number of voting rights and share capital in Bavarian Nordic A/S March 23, 2016 | Company Announcements
Bavarian Nordic A/S – Notice Convening Ordinary General Meeting